Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.

Martin A, Lavoie L, Goetghebeur M, Schellenberg R.

Transfus Med. 2013 Feb;23(1):55-60. doi: 10.1111/j.1365-3148.2012.01201.x. Epub 2012 Nov 20.

3.

Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Perraudin C, Bourdin A, Spertini F, Berger J, Bugnon O.

J Clin Immunol. 2016 Jul;36(5):502-10. doi: 10.1007/s10875-016-0288-z. Epub 2016 May 2.

PMID:
27139500
4.

Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.

Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K.

Clin Ther. 2014 Nov 1;36(11):1616-24. doi: 10.1016/j.clinthera.2014.08.007. Epub 2014 Sep 16.

5.

Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.

Krishnarajah G, Lehmann JK, Ellman B, Bhak RH, DerSarkissian M, Leader D Jr, Bullinger AL, Sheng Duh M.

Am J Manag Care. 2016 Oct;22(15 Suppl):s475-s481.

6.

Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.

Windegger TM, Lambooy CA, Hollis L, Morwood K, Weston H, Fung YL.

Transfus Med Rev. 2017 Jan;31(1):45-50. doi: 10.1016/j.tmrv.2016.06.006. Epub 2016 Jul 2. Review.

PMID:
27450021
7.

Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.

Kearns S, Kristofek L, Bolgar W, Seidu L, Kile S.

J Manag Care Spec Pharm. 2017 Apr;23(4):400-406. doi: 10.18553/jmcp.2017.23.4.400.

8.

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".

Bienvenu B, Cozon G, Hoarau C, Pasquet M, Cherin P, Clerson P, Hachulla E, Crave JC, Delain JC, Jaussaud R.

Orphanet J Rare Dis. 2016 Jun 22;11(1):83. doi: 10.1186/s13023-016-0452-9.

9.

Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.

Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, Martín-Nalda A, Oliveras M, Martinez-Cutillas J, Figueras C.

J Clin Immunol. 2014 Nov;34(8):1015-7. doi: 10.1007/s10875-014-0096-2. Epub 2014 Sep 5.

PMID:
25190197
10.

Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, Costa-Carvalho BT, Granert C, Haag S, Hernández D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M.

J Allergy Clin Immunol. 2004 Oct;114(4):936-42.

PMID:
15480339
11.

Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.

Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, Tajahmady A, Thomas C, Suarez F, Pellier I, Hermine O, Aladjidi N, Mahlaoui N, Fischer A; French PID study group CEREDIH.

Clin Exp Immunol. 2010 May;160(2):240-5. doi: 10.1111/j.1365-2249.2009.04079.x. Epub 2009 Dec 16.

12.

Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N.

J Clin Immunol. 2012 Dec;32(6):1180-92. doi: 10.1007/s10875-012-9720-1. Epub 2012 Jun 23. Review.

PMID:
22730009
13.

Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.

Bezrodnik L, Gómez Raccio A, Belardinelli G, Regairaz L, Díaz Ballve D, Seminario G, Moreira I, Riganti C, Cantisano C, Díaz H, Di Giovanni D.

J Clin Immunol. 2013 Oct;33(7):1216-22. doi: 10.1007/s10875-013-9916-z. Epub 2013 Jul 12.

PMID:
23846854
14.

Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases.

Haddad É, Barnes D, Kafal A.

Transfus Apher Sci. 2012 Jun;46(3):315-21. doi: 10.1016/j.transci.2012.03.022. Epub 2012 Apr 12. Review.

PMID:
22503304
15.

Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.

Stein MR, Koterba A, Rodden L, Berger M.

Postgrad Med. 2011 Sep;123(5):186-93. doi: 10.3810/pgm.2011.09.2474.

PMID:
21904101
16.

[Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].

Maroto Hernando M, Soler Palacín P, Martin Nalda N, Oliveras Arenas M, Español Boren T, Figueras Nadal C.

An Pediatr (Barc). 2009 Feb;70(2):111-9. doi: 10.1016/j.anpedi.2008.11.011. Epub 2009 Feb 3. Spanish. Erratum in: An Pediatr (Barc). 2010 Mar;72(3):237-8.

17.

Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.

Kanegane H, Imai K, Yamada M, Takada H, Ariga T, Bexon M, Rojavin M, Hu W, Kobayashi M, Lawo JP, Nonoyama S, Hara T, Miyawaki T.

J Clin Immunol. 2014 Feb;34(2):204-11. doi: 10.1007/s10875-013-9985-z. Epub 2014 Feb 7.

18.

20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review.

Song J, Zhang L, Li Y, Quan S, Liang Y, Zeng L, Liu Y.

Int Immunopharmacol. 2015 Apr;25(2):457-64. doi: 10.1016/j.intimp.2015.01.016. Epub 2015 Jan 27. Review.

PMID:
25633961
19.

A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?

Pasquet M, Pellier I, Aladjidi N, Auvrignon A, Cherin P, Clerson P, Cozon GJN, Jaussaud R, Bienvenu B, Hoarau C.

Patient Prefer Adherence. 2017 Jul 10;11:1171-1180. doi: 10.2147/PPA.S123363. eCollection 2017.

20.

Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.

Hadden RD, Marreno F.

Ther Adv Neurol Disord. 2015 Jan;8(1):14-9. doi: 10.1177/1756285614563056.

Supplemental Content

Support Center